Investigating the prognostic impact of NY-ESO-1 expression and HLA subtypes in metastatic synovial sarcoma.
Fiche publication
Date publication
août 2024
Journal
ESMO open
Auteurs
Membres identifiés du Cancéropôle Est :
Dr LEROUX Agnès
Tous les auteurs :
Dufresne A, Pokras S, Meurgey A, Chabaud S, Toulmonde M, Bompas E, Le Cesne A, Robin YM, Duffaud F, Valentin T, El Zein S, Leroux A, Dubray-Longeras P, Firmin N, de Pinieux G, Noal S, Delfour C, Bollard J, Tonon L, Biette A, Gadot N, Attignon V, Jean-Denis M, Woessner M, Klohe E, Thayaparan T, Eleftheriadou I, Blouch K, Nathenson MJ, Blay JY
Lien Pubmed
Résumé
To better understand the importance of New York esophageal squamous cell carcinoma 1 (NY-ESO-1) and human leukocyte antigen (HLA) subtype in treatment decision making, further investigation of their prevalence and prognostic impact among patients with metastatic synovial sarcoma (mSS) is needed.
Mots clés
HLA subtypes, NY-ESO-1 expression, adoptive T-cell therapy, metastatic synovial sarcoma
Référence
ESMO Open. 2024 08 16;9(8):103645